Evidence map›Paper›PMID 32849924›Full record

ReviewThe EPMA journal2020

Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine.

Judita Kinkorová, Ondřej Topolčan

Abstract readReview
In one paragraph

Review in The EPMA journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Judita KinkorováLaboratory of Immunoanalysis, University Hospital in Pilsen, Edvarda Beneše 1128/13, 30599 Pilsen, Czech Republic.ORCID https://orcid.org/0000-0002-9152-3338
Ondřej TopolčanLaboratory of Immunoanalysis, University Hospital in Pilsen, Edvarda Beneše 1128/13, 30599 Pilsen, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biobanking is entering the new era-era of big data. New technologies, techniques, and knowledge opened the potential of the whole domain of biobanking. Biobanks collect, analyse, store, and share the samples and associated data. Both samples and especially associated data are growing enormously, and new innovative approaches are required to handle samples and to utilize the potential of biobanking data. The data reached the quantity and quality of big data, and the scientists are facing the questions how to use them more efficiently, both retrospectively and prospectively with the aim to discover new preventive methods, optimize treatment, and follow up and to optimize healthcare processes. Biobanking in the era of big data contribute to the development of predictive, preventive, and personalised medicine, for every patient providing the right treatment at the right time. Biobanking in the era of big data contributes to the paradigm shift towards personalising of healthcare.

Indexed as

Artificial intelligenceBig dataBiobanksBiomedical researchCancerComputation analysisDiabetesEconomyHealthcareImplementationInformation technologiesInnovationsLiquid biopsyMachine learningPatient benefitsPersonalised treatment algorithmsPopulation screeningPredictive preventive personalised medicineServicesStroke

Identifiers

PMID32849924
PMCPMC7429593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.